Total Payments
$665,374
2024 Payments
$120,521
Companies
38
Transactions
1,776
Medicare Patients
6,954
Medicare Billing
$2.1M
Payment Breakdown by Category
Other$502,605 (75.5%)
Travel$51,626 (7.8%)
Research$45,289 (6.8%)
Food & Beverage$34,081 (5.1%)
Consulting$31,571 (4.7%)
Education$201.38 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $502,605 | 181 | 75.5% |
| Travel and Lodging | $51,626 | 247 | 7.8% |
| Unspecified | $45,289 | 18 | 6.8% |
| Food and Beverage | $34,081 | 1,307 | 5.1% |
| Consulting Fee | $31,571 | 13 | 4.7% |
| Education | $201.38 | 10 | 0.0% |
Payments by Type
General
$620,085
1,758 transactions
Research
$45,289
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $260,097 | 460 | $0 (2024) |
| GENZYME CORPORATION | $102,579 | 150 | $0 (2024) |
| GlaxoSmithKline, LLC. | $81,748 | 215 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $67,044 | 150 | $0 (2024) |
| Glenmark Pharmaceuticals Inc. | $38,950 | 6 | $0 (2017) |
| Shire North American Group Inc | $36,311 | 99 | $0 (2019) |
| Pharming Healthcare, Inc. | $20,192 | 27 | $0 (2024) |
| Amgen Inc. | $11,922 | 40 | $0 (2024) |
| Genentech USA, Inc. | $8,849 | 26 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $7,043 | 55 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $120,521 | 255 | AstraZeneca Pharmaceuticals LP ($77,234) |
| 2023 | $107,599 | 266 | AstraZeneca Pharmaceuticals LP ($38,187) |
| 2022 | $104,459 | 252 | AstraZeneca Pharmaceuticals LP ($42,163) |
| 2021 | $51,224 | 157 | AstraZeneca Pharmaceuticals LP ($20,093) |
| 2020 | $35,107 | 166 | GlaxoSmithKline, LLC. ($10,037) |
| 2019 | $86,954 | 232 | AstraZeneca Pharmaceuticals LP ($42,888) |
| 2018 | $70,800 | 214 | AstraZeneca Pharmaceuticals LP ($29,892) |
| 2017 | $88,710 | 234 | Glenmark Pharmaceuticals Inc. ($38,950) |
All Payment Transactions
1,776 individual payment records from CMS Open Payments — Page 1 of 72
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: BIOLOGIC | ||||||
| 12/16/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.45 | General |
| Category: RESPIRATORY | ||||||
| 12/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,381.00 | General |
| Category: Immunology | ||||||
| 12/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $196.40 | General |
| Category: Immunology | ||||||
| 12/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $124.80 | General |
| Category: Immunology | ||||||
| 12/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | Cash or cash equivalent | $99.29 | General |
| Category: Immunology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: Respiratory | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,381.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $993.17 | General |
| Category: Immunology | ||||||
| 12/10/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $108.80 | General |
| Category: Immunology | ||||||
| 12/10/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: Immunology | ||||||
| 12/10/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Respiratory | ||||||
| 12/07/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: Respiratory | ||||||
| 12/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $42.90 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $297.91 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $178.89 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: Immunology | ||||||
| 11/20/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: Immunology | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $2.33 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: Immunology | ||||||
| 11/12/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GSP 301-303 | Glenmark Pharmaceuticals Inc. | $38,950 | 6 |
| An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment | Circassia Pharmaceuticals Inc | $4,127 | 9 |
| An Open-label, Randomized, Actual Use Study of Dupilumab Auto-injector Device in Patients With Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $2,212 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,645 | 24,415 | $1.9M | $624,386 |
| 2022 | 19 | 1,615 | 20,462 | $1.7M | $513,298 |
| 2021 | 24 | 1,856 | 21,091 | $2.1M | $630,244 |
| 2020 | 23 | 1,838 | 18,024 | $993,600 | $305,709 |
Total Patients
6,954
Total Services
83,992
Medicare Billing
$2.1M
Procedure Codes
85
All Medicare Procedures & Services
85 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 14 | 7,365 | $441,900 | $222,705 | 50.4% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2023 | 11 | 1,561 | $654,525 | $207,067 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 265 | 461 | $138,300 | $42,208 | 30.5% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 124 | 3,777 | $147,303 | $39,692 | 26.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 330 | 477 | $78,705 | $30,049 | 38.2% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 81 | 6,138 | $135,036 | $18,306 | 13.6% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 118 | 2,164 | $84,396 | $16,473 | 19.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 96 | 96 | $38,400 | $11,316 | 29.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 183 | 256 | $47,360 | $6,825 | 14.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 44 | 489 | $48,900 | $5,003 | 10.2% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 22 | 141 | $14,805 | $4,898 | 33.1% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 22 | 139 | $20,850 | $4,858 | 23.3% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2023 | 184 | 265 | $21,465 | $3,374 | 15.7% |
| 95115 | Professional service for single injection of allergen | Office | 2023 | 29 | 443 | $11,961 | $2,770 | 23.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 28 | 28 | $8,400 | $2,339 | 27.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 47 | 58 | $6,670 | $2,272 | 34.1% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 20 | 65 | $6,825 | $1,762 | 25.8% |
| 95044 | Test for allergy using skin patch | Office | 2023 | 13 | 475 | $9,025 | $1,665 | 18.5% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2023 | 14 | 17 | $1,700 | $804.48 | 47.3% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2022 | 14 | 6,072 | $364,320 | $181,149 | 49.7% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2022 | 11 | 1,263 | $663,075 | $166,952 | 25.2% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 97 | 2,870 | $111,930 | $34,273 | 30.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 330 | 499 | $82,335 | $31,842 | 38.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 192 | 278 | $83,400 | $25,208 | 30.2% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 83 | 5,876 | $129,272 | $17,298 | 13.4% |
About Dr. Christopher Smith, M.D
Dr. Christopher Smith, M.D is a Allergy healthcare provider based in Horseheads, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1679675995.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Smith, M.D has received a total of $665,374 in payments from pharmaceutical and medical device companies, with $120,521 received in 2024. These payments were reported across 1,776 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($502,605).
As a Medicare-enrolled provider, Smith has provided services to 6,954 Medicare beneficiaries, totaling 83,992 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 85 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy
- Location Horseheads, NY
- Active Since 09/05/2006
- Last Updated 09/22/2020
- Taxonomy Code 207KA0200X
- Entity Type Individual
- NPI Number 1679675995
Products in Payments
- DUPIXENT (Biological) $120,771
- FASENRA (Biological) $94,864
- NUCALA (Biological) $80,783
- FASENRA (Drug) $80,653
- TEZSPIRE (Biological) $58,081
- AIRSUPRA (Drug) $36,092
- DUPIXENT DUPILUMAB INJECTION (Biological) $32,372
- CUVITRU (Biological) $21,770
- JOENJA (Drug) $19,770
- Xolair (Biological) $15,641
- DUPIXENT (Drug) $15,284
- CINRYZE (Drug) $9,303
- HYQVIA (Biological) $5,595
- SPIRIVA RESPIMAT (Drug) $3,762
- Xembify (Biological) $2,846
- XOLAIR (Biological) $1,909
- GARDASIL 9 (Biological) $1,716
- V114 (Biological) $1,447
- EUCRISA (Drug) $723.49
- TRELEGY ELLIPTA (Drug) $647.93
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.